Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SGMTthis companySagimet Biosciences Inc.	$10.74	-3.75×	1.72×	0×	-3.07×	-90.1%	0.0%	0.0%	0.0%	-45.8%	-51.0%	-23.8%	0×	0.68×	0×	22.82×	0.0%	2	24.96	2	C+
ACHVAchieve Life Sciences, Inc.	$6.82	-3.98×	10.07×	0×	-3.93×	-98.2%	0.0%	0.0%	0.0%	-254.0%	-150.5%	-22.8%	0.69×	0.11×	-67.01×	4.39×	0.0%	2	-2.53	2	C
ARCTArcturus Therapeutics Holdings Inc.	$9.87	-2.55×	0.78×	2.5×	0.61×	-135.5%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.16	2	C
ASMBAssembly Biosciences, Inc.	$21.60	-61.84×	1.84×	5.27×	-54.31×	-353.5%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.66	2	B-
AVIRAtea Pharmaceuticals, Inc.	$4.47	-1.84×	1.06×	0×	-1.19×	-77.0%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	1	6.93	3	B-
FHTXFoghorn Therapeutics Inc.	$2.08	-4.58×	-3.13×	11×	-4.24×	-780.0%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	5	-2.6	1	C-
Peer median	—	-3.98×	1.06×	2.5×	-3.93×	-135.5%	89.2%	-16.8%	-8.5%	-30.7%	-58.9%	-25.3%	0.01×	0.58×	0×	5.22×	0.0%	2	-0.16	2	—